Press releases
  • 27 May 2025  ·  Regulatory information

    Guard Therapeutics reports positive outcome from second planned safety review in the Phase 2b POINTER study

    Read more
  • 21 May 2025

    Guard Therapeutics to present Phase 2b POINTER study design at scientific conference

    Read more
  • 11 Apr 2025  ·  Regulatory information

    Guard Therapeutics announces changes in number of shares and votes

    Read more
  • 04 Apr 2025  ·  Regulatory information

    Guard Therapeutics announces outcome of the rights issue

    Read more
Show more
In focus
  • 17 Oct 2024 / Presentation

    Guard presents at Redeye Theme "Cardiovascular & Metabolic Diseases Event 2024"

    Read more
  • 23 Sep 2024 / Presentation

    CEO Tobias Agervald appears on BiotechTV

    Read more
  • 19 Sep 2024 / Presentation

    Presentation at Pareto Securities' 15th Annual Healthcare Conference

    Read more
  • 30 Jan 2024 / Presentation

    Guard Therapeutics R&D update January 30, 2024

    Read more
Show more
Upcoming events
  • 04 Jun 2025

    Guard presents at the 62nd ERA Congress, Vienna, June 4-7

    Read more
  • 16 Jun 2025

    Guard attends the Bio International, Boston, June 16-19

    Read more
  • 21 Aug 2025

    Interim report January-June 2025

    Read more
  • 01 Sep 2025

    Guard presents at DNB Carnegie Small Cap Day September 1st